<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32605090</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>13</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jun</Month>
              <Day>27</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeted Therapy in Melanoma and Mechanisms of Resistance.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">4576</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21134576</ELocationID>
        <Abstract>
          <AbstractText>The common mutation <i>BRAFV600</i> in primary melanomas activates the mitogen-activated protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the introduction of proto-oncogene B-Raf (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors (BRAFi and MEKi) was a breakthrough in the treatment of these cancers. However, 15-20% of tumors harbor primary resistance to this therapy, and moreover, patients develop acquired resistance to treatment. Understanding the molecular phenomena behind resistance to BRAFi/MEKis is indispensable in order to develop novel targeted therapies. Most often, resistance develops due to either the reactivation of the MAPK/ERK pathway or the activation of alternative kinase signaling pathways including phosphatase and tensin homolog (PTEN), neurofibromin 1 (NF-1) or RAS signaling. The hyperactivation of tyrosine kinase receptors, such as the receptor of the platelet-derived growth factor β (PDFRβ), insulin-like growth factor 1 receptor (IGF-1R) and the receptor for hepatocyte growth factor (HGF), lead to the induction of the AKT/3-phosphoinositol kinase (PI3K) pathway. Another pathway resulting in BRAFi/MEKi resistance is the hyperactivation of epidermal growth factor receptor (EGFR) signaling or the deregulation of microphthalmia-associated transcription factor (MITF).</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Czarnecka</LastName>
            <ForeName>Anna M</ForeName>
            <Initials>AM</Initials>
            <Identifier Source="ORCID">0000-0002-2107-3810</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Soft Tissue/Bone, Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bartnik</LastName>
            <ForeName>Ewa</ForeName>
            <Initials>E</Initials>
            <Identifier Source="ORCID">0000-0003-0489-7102</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, 02-106 Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fiedorowicz</LastName>
            <ForeName>Michał</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-5755-3608</Identifier>
            <AffiliationInfo>
              <Affiliation>Small Animal Magnetic Resonance Imaging Laboratory, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Interinstitute Laboratory of New Diagnostic Applications of MRI, Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, 02-109 Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rutkowski</LastName>
            <ForeName>Piotr</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-8920-5429</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Soft Tissue/Bone, Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000715470">MAS1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000090063">Proto-Oncogene Mas</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.12.2</RegistryNumber>
          <NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020929" MajorTopicYN="N">Mitogen-Activated Protein Kinase Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090063" MajorTopicYN="N">Proto-Oncogene Mas</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">BRAF</Keyword>
        <Keyword MajorTopicYN="N">MAPK</Keyword>
        <Keyword MajorTopicYN="N">MEK</Keyword>
        <Keyword MajorTopicYN="N">drug resistance</Keyword>
        <Keyword MajorTopicYN="N">melanoma</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32605090</ArticleId>
        <ArticleId IdType="pmc">PMC7369697</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms21134576</ArticleId>
        <ArticleId IdType="pii">ijms21134576</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Craig S., Earnshaw C.H., Viros A. Ultraviolet light and melanoma. J. Pathol. 2018;244:578–585. doi: 10.1002/path.5039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.5039</ArticleId>
            <ArticleId IdType="pubmed">29380860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., Cho K.H., Aiba S., Brocker E.B., LeBoit P.E., et al.  Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005;353:2135–2147. doi: 10.1056/NEJMoa050092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa050092</ArticleId>
            <ArticleId IdType="pubmed">16291983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayward N.K., Wilmott J.S., Waddell N., Johansson P.A., Field M.A., Nones K., Patch A.M., Kakavand H., Alexandrov L.B., Burke H., et al.  Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175–180. doi: 10.1038/nature22071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature22071</ArticleId>
            <ArticleId IdType="pubmed">28467829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiappetta C., Proietti I., Soccodato V., Puggioni C., Zaralli R., Pacini L., Porta N., Skroza N., Petrozza V., Potenza C., et al.  BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma. Appl. Immunohistochem. Mol. Morphol. 2015;23:172–177. doi: 10.1097/PAI.0000000000000071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAI.0000000000000071</ArticleId>
            <ArticleId IdType="pmc">PMC4482453</ArticleId>
            <ArticleId IdType="pubmed">24710085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffin M., Scotto D., Josephs D.H., Mele S., Crescioli S., Bax H.J., Pellizzari G., Wynne M.D., Nakamura M., Hoffmann R.M., et al.  BRAF inhibitors: Resistance and the promise of combination treatments for melanoma. Oncotarget. 2017;8:78174–78192. doi: 10.18632/oncotarget.19836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.19836</ArticleId>
            <ArticleId IdType="pmc">PMC5652848</ArticleId>
            <ArticleId IdType="pubmed">29100459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mackiewicz J., Mackiewicz A. BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemp. Oncol. 2018;22:68–72. doi: 10.5114/wo.2018.73890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/wo.2018.73890</ArticleId>
            <ArticleId IdType="pmc">PMC5885075</ArticleId>
            <ArticleId IdType="pubmed">29628797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium  Pan-cancer analysis of whole genomes. Nature. 2020;578:82–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7025898</ArticleId>
            <ArticleId IdType="pubmed">32025007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amaral T., Sinnberg T., Meier F., Krepler C., Levesque M., Niessner H., Garbe C. The mitogen-activated protein kinase pathway in melanoma part I-Activation and primary resistance mechanisms to BRAF inhibition. Eur. J. Cancer. 2017;73:85–92. doi: 10.1016/j.ejca.2016.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2016.12.010</ArticleId>
            <ArticleId IdType="pubmed">28169047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winder M., Viros A. Mechanisms of Drug Resistance in Melanoma. Handb. Exp. Pharmacol. 2018;249:91–108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28275910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brash D.E. UV signature mutations. Photochem. Photobiol. 2015;91:15–26. doi: 10.1111/php.12377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/php.12377</ArticleId>
            <ArticleId IdType="pmc">PMC4294947</ArticleId>
            <ArticleId IdType="pubmed">25354245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swick J.M., Maize J.C., Sr. Molecular biology of melanoma. J. Am. Acad. Dermatol. 2012;67:1049–1054. doi: 10.1016/j.jaad.2011.06.047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2011.06.047</ArticleId>
            <ArticleId IdType="pubmed">22459362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A., Flaherty K.T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 2011;8:426–433. doi: 10.1038/nrclinonc.2011.69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2011.69</ArticleId>
            <ArticleId IdType="pubmed">21606968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al.  Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. doi: 10.1038/nature00766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature00766</ArticleId>
            <ArticleId IdType="pubmed">12068308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaman A., Wu W., Bivona T.G. Targeting Oncogenic BRAF: Past, Present, and Future. Cancers. 2019;11 doi: 10.3390/cancers11081197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11081197</ArticleId>
            <ArticleId IdType="pmc">PMC6721448</ArticleId>
            <ArticleId IdType="pubmed">31426419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng L., Lopez-Beltran A., Massari F., MacLennan G.T., Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine. Mod. Pathol. 2018;31:24–38. doi: 10.1038/modpathol.2017.104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2017.104</ArticleId>
            <ArticleId IdType="pmc">PMC5758899</ArticleId>
            <ArticleId IdType="pubmed">29148538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozak K., Rutkowski P. Why Do We Need a New BRAF-MEK Inhibitor Combination in Melanoma? Oncol. Clin. Pract. 2019;15:115–119. doi: 10.5603/OCP.2018.0054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/OCP.2018.0054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozak K., Świtaj T., Koseła-Paterczyk H., Jagodzińska-Mucha P., Rogala P., Teterycz P., Rutkowski P. Podsumowanie Doświadczeń w Stosowaniu Inhibitorów BRAF/MEK u Chorych na Czerniaka w Ramach Dostępnych Programów Lekowych.  [(accessed on 24 June 2020)];Oncol. Clin. Pract. 2020  Available online:  https://journals.viamedica.pl/onkologia_w_praktyce_klin_edu/article/view/68612.</Citation>
        </Reference>
        <Reference>
          <Citation>Long G.V., Menzies A.M., Nagrial A.M., Haydu L.E., Hamilton A.L., Mann G.J., Hughes T.M., Thompson J.F., Scolyer R.A., Kefford R.F. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 2011;29:1239–1246. doi: 10.1200/JCO.2010.32.4327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2010.32.4327</ArticleId>
            <ArticleId IdType="pubmed">21343559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasquali S., Hadjinicolaou A.V., Chiarion Sileni V., Rossi C.R., Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst. Rev. 2018;2:CD011123. doi: 10.1002/14651858.CD011123.pub2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD011123.pub2</ArticleId>
            <ArticleId IdType="pmc">PMC6491081</ArticleId>
            <ArticleId IdType="pubmed">29405038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J., Brown M.P., Arance A.M., Hauschild A., Queirolo P., Vecchio M.D., Ascierto P.A., Krajsova I., Schachter J., Neyns B., et al.  An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: Final analysis and a validated prognostic scoring system. Eur. J. Cancer. 2019;107:175–185. doi: 10.1016/j.ejca.2018.11.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2018.11.018</ArticleId>
            <ArticleId IdType="pubmed">30580112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hauschild A., Ascierto P.A., Schadendorf D., Grob J.J., Ribas A., Kiecker F., Dutriaux C., Demidov L.V., Lebbe C., Rutkowski P., et al.  Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. Eur. J. Cancer. 2020;125:114–120. doi: 10.1016/j.ejca.2019.10.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2019.10.033</ArticleId>
            <ArticleId IdType="pubmed">31864178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert C., Grob J.J., Stroyakovskiy D., Karaszewska B., Hauschild A., Levchenko E., Chiarion Sileni V., Schachter J., Garbe C., Bondarenko I., et al.  Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N. Engl. J. Med. 2019;381:626–636. doi: 10.1056/NEJMoa1904059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1904059</ArticleId>
            <ArticleId IdType="pubmed">31166680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan X.Y., Singh A., Osman N., Piva T.J. Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. Int. J. Mol. Sci. 2017;18:1527.  doi: 10.3390/ijms18071527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18071527</ArticleId>
            <ArticleId IdType="pmc">PMC5536016</ArticleId>
            <ArticleId IdType="pubmed">28708099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ascierto P.A., Dummer R., Gogas H.J., Flaherty K.T., Arance A., Mandala M., Liszkay G., Garbe C., Schadendorf D., Krajsova I., et al.  Update on tolerability and overall survival in COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur. J. Cancer. 2020;126:33–44. doi: 10.1016/j.ejca.2019.11.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2019.11.016</ArticleId>
            <ArticleId IdType="pubmed">31901705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel H., Yacoub N., Mishra R., White A., Long Y., Alanazi S., Garrett J.T. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers. 2020;12:482.  doi: 10.3390/cancers12020482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12020482</ArticleId>
            <ArticleId IdType="pmc">PMC7072236</ArticleId>
            <ArticleId IdType="pubmed">32092958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Consortium A.P.G. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7:818–831. doi: 10.1158/2159-8290.CD-17-0151.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-17-0151</ArticleId>
            <ArticleId IdType="pmc">PMC5611790</ArticleId>
            <ArticleId IdType="pubmed">28572459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozar I., Margue C., Rothengatter S., Haan C., Kreis S. Many ways to resistance: How melanoma cells evade targeted therapies. Biochim. Biophys. Acta. Rev. Cancer. 2019;1871:313–322. doi: 10.1016/j.bbcan.2019.02.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbcan.2019.02.002</ArticleId>
            <ArticleId IdType="pubmed">30776401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caporali S., Alvino E., Lacal P.M., Levati L., Giurato G., Memoli D., Caprini E., Antonini Cappellini G.C., D’Atri S. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int. J. Oncol. 2016;49:1164–1174. doi: 10.3892/ijo.2016.3594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2016.3594</ArticleId>
            <ArticleId IdType="pubmed">27572607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartnik E., Fiedorowicz M., Czarnecka A.M. Mechanisms of Melanoma Resistance to Treatment with BRAF and MEK Inhibitors. Nowotwory J. Oncol. 2019;69:133–141. doi: 10.5603/NJO.2019.0025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/NJO.2019.0025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi H., Moriceau G., Kong X., Lee M.K., Lee H., Koya R.C., Ng C., Chodon T., Scolyer R.A., Dahlman K.B., et al.  Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 2012;3:724. doi: 10.1038/ncomms1727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms1727</ArticleId>
            <ArticleId IdType="pmc">PMC3530385</ArticleId>
            <ArticleId IdType="pubmed">22395615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pupo G.M., Boyd S.C., Fung C., Carlino M.S., Menzies A.M., Pedersen B., Johansson P., Hayward N.K., Kefford R.F., Scolyer R.A., et al.  Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomark. Res. 2017;5:17. doi: 10.1186/s40364-017-0098-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40364-017-0098-3</ArticleId>
            <ArticleId IdType="pmc">PMC5426037</ArticleId>
            <ArticleId IdType="pubmed">28503307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vido M.J., Le K., Hartsough E.J., Aplin A.E. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Rep. 2018;25:1501–1510.e3. doi: 10.1016/j.celrep.2018.10.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.10.049</ArticleId>
            <ArticleId IdType="pmc">PMC6261462</ArticleId>
            <ArticleId IdType="pubmed">30404005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson D.B., Menzies A.M., Zimmer L., Eroglu Z., Ye F., Zhao S., Rizos H., Sucker A., Scolyer R.A., Gutzmer R., et al.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur. J. Cancer. 2015;51:2792–2799. doi: 10.1016/j.ejca.2015.08.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2015.08.022</ArticleId>
            <ArticleId IdType="pmc">PMC4666799</ArticleId>
            <ArticleId IdType="pubmed">26608120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poulikakos P.I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., Shi H., Atefi M., Titz B., Gabay M.T., et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature. 2011;480:387–390. doi: 10.1038/nature10662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10662</ArticleId>
            <ArticleId IdType="pmc">PMC3266695</ArticleId>
            <ArticleId IdType="pubmed">22113612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luco R.F., Allo M., Schor I.E., Kornblihtt A.R., Misteli T. Epigenetics in alternative pre-mRNA splicing. Cell. 2011;144:16–26. doi: 10.1016/j.cell.2010.11.056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.11.056</ArticleId>
            <ArticleId IdType="pmc">PMC3038581</ArticleId>
            <ArticleId IdType="pubmed">21215366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian Y., Guo W. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma. Med. Sci. Monit. 2020;26:e920957. doi: 10.12659/MSM.920957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12659/MSM.920957</ArticleId>
            <ArticleId IdType="pmc">PMC7169438</ArticleId>
            <ArticleId IdType="pubmed">32273491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corcoran R.B., Dias-Santagata D., Bergethon K., Iafrate A.J., Settleman J., Engelman J.A. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 2010;3:ra84. doi: 10.1126/scisignal.2001148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2001148</ArticleId>
            <ArticleId IdType="pmc">PMC3372405</ArticleId>
            <ArticleId IdType="pubmed">21098728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim A., Cohen M.S. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Expert Opin. Drug Discov. 2016;11:907–916. doi: 10.1080/17460441.2016.1201057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17460441.2016.1201057</ArticleId>
            <ArticleId IdType="pmc">PMC5443413</ArticleId>
            <ArticleId IdType="pubmed">27327499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bezniakow N., Gos M., Obersztyn E. The RASopathies as an example of RAS/MAPK pathway disturbances-clinical presentation and molecular pathogenesis of selected syndromes. Dev. Period Med. 2014;18:285–296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25182392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez J.N., Wang T., Cohen M.S. BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers. Drugs. 2018;78:549–566. doi: 10.1007/s40265-018-0884-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-018-0884-8</ArticleId>
            <ArticleId IdType="pmc">PMC6080616</ArticleId>
            <ArticleId IdType="pubmed">29488071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi H., Hugo W., Kong X., Hong A., Koya R.C., Moriceau G., Chodon T., Guo R., Johnson D.B., Dahlman K.B., et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4:80–93. doi: 10.1158/2159-8290.CD-13-0642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-13-0642</ArticleId>
            <ArticleId IdType="pmc">PMC3936420</ArticleId>
            <ArticleId IdType="pubmed">24265155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma V., Young L., Cavadas M., Owen K., Reproducibility Project: Cancer Biology  Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Elife. 2016;5:e11414. doi: 10.7554/eLife.11414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.11414</ArticleId>
            <ArticleId IdType="pmc">PMC4811761</ArticleId>
            <ArticleId IdType="pubmed">26999821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., Emery C.M., Stransky N., Cogdill A.P., Barretina J., et al.  COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:968–972. doi: 10.1038/nature09627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09627</ArticleId>
            <ArticleId IdType="pmc">PMC3058384</ArticleId>
            <ArticleId IdType="pubmed">21107320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potentially Actionable MAP3K8 Alterations Are Common in Spitzoid Melanoma. Cancer Discov. 2019;9:574.</Citation>
        </Reference>
        <Reference>
          <Citation>Lehmann B.D., Shaver T.M., Johnson D.B., Li Z., Gonzalez-Ericsson P.I., Sanchez V., Shyr Y., Sanders M.E., Pietenpol J.A. Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations. Mol. Cancer Res. 2019;17:1842–1853. doi: 10.1158/1541-7786.MCR-19-0257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-19-0257</ArticleId>
            <ArticleId IdType="pmc">PMC6726520</ArticleId>
            <ArticleId IdType="pubmed">31186280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molina J.R., Adjei A.A. The Ras/Raf/MAPK pathway. J. Thorac. Oncol. 2006;1:7–9. doi: 10.1016/S1556-0864(15)31506-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1556-0864(15)31506-9</ArticleId>
            <ArticleId IdType="pubmed">17409820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fedorenko I.V., Paraiso K.H., Smalley K.S. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem. Pharm. 2011;82:201–209. doi: 10.1016/j.bcp.2011.05.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2011.05.015</ArticleId>
            <ArticleId IdType="pmc">PMC4001781</ArticleId>
            <ArticleId IdType="pubmed">21635872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corcoran R.B., Settleman J., Engelman J.A. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget. 2011;2:336–346. doi: 10.18632/oncotarget.262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.262</ArticleId>
            <ArticleId IdType="pmc">PMC3248170</ArticleId>
            <ArticleId IdType="pubmed">21505228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.K., Attar N., Sazegar H., et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973–977. doi: 10.1038/nature09626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09626</ArticleId>
            <ArticleId IdType="pmc">PMC3143360</ArticleId>
            <ArticleId IdType="pubmed">21107323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romano E., Pradervand S., Paillusson A., Weber J., Harshman K., Muehlethaler K., Speiser D., Peters S., Rimoldi D., Michielin O. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2013;19:5749–5757. doi: 10.1158/1078-0432.CCR-13-0661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0661</ArticleId>
            <ArticleId IdType="pubmed">23948972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X., Gimotty P.A., Kee D., et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18:683–695. doi: 10.1016/j.ccr.2010.11.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2010.11.023</ArticleId>
            <ArticleId IdType="pmc">PMC3026446</ArticleId>
            <ArticleId IdType="pubmed">21156289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spagnolo F., Ghiorzo P., Orgiano L., Pastorino L., Picasso V., Tornari E., Ottaviano V., Queirolo P. BRAF-mutant melanoma: Treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther. 2015;8:157–168. doi: 10.2147/OTT.S39096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S39096</ArticleId>
            <ArticleId IdType="pmc">PMC4303458</ArticleId>
            <ArticleId IdType="pubmed">25653539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen L.K., Kholodenko B.N., von Kriegsheim A. Rac1 and RhoA: Networks, loops and bistability. Small Gtpases. 2018;9:316–321. doi: 10.1080/21541248.2016.1224399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21541248.2016.1224399</ArticleId>
            <ArticleId IdType="pmc">PMC5997137</ArticleId>
            <ArticleId IdType="pubmed">27533896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watson I.R., Li L., Cabeceiras P.K., Mahdavi M., Gutschner T., Genovese G., Wang G., Fang Z., Tepper J.M., Stemke-Hale K., et al.  The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res. 2014;74:4845–4852. doi: 10.1158/0008-5472.CAN-14-1232-T.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-1232-T</ArticleId>
            <ArticleId IdType="pmc">PMC4167745</ArticleId>
            <ArticleId IdType="pubmed">25056119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Allen E.M., Wagle N., Sucker A., Treacy D.J., Johannessen C.M., Goetz E.M., Place C.S., Taylor-Weiner A., Whittaker S., Kryukov G.V., et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4:94–109. doi: 10.1158/2159-8290.CD-13-0617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-13-0617</ArticleId>
            <ArticleId IdType="pmc">PMC3947264</ArticleId>
            <ArticleId IdType="pubmed">24265153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lionarons D.A., Hancock D.C., Rana S., East P., Moore C., Murillo M.M., Carvalho J., Spencer-Dene B., Herbert E., Stamp G., et al.  RAC1(P29S) Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. Cancer Cell. 2019;36:68–83.e9. doi: 10.1016/j.ccell.2019.05.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2019.05.015</ArticleId>
            <ArticleId IdType="pmc">PMC6617390</ArticleId>
            <ArticleId IdType="pubmed">31257073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aguissa-Toure A.H., Li G. Genetic alterations of PTEN in human melanoma. Cell Mol. Life Sci. 2012;69:1475–1491. doi: 10.1007/s00018-011-0878-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-011-0878-0</ArticleId>
            <ArticleId IdType="pubmed">22076652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paraiso K.H., Xiang Y., Rebecca V.W., Abel E.V., Chen Y.A., Munko A.C., Wood E., Fedorenko I.V., Sondak V.K., Anderson A.R., et al.  PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71:2750–2760. doi: 10.1158/0008-5472.CAN-10-2954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-10-2954</ArticleId>
            <ArticleId IdType="pmc">PMC3070772</ArticleId>
            <ArticleId IdType="pubmed">21317224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nathanson K.L., Martin A.M., Wubbenhorst B., Greshock J., Letrero R., D’Andrea K., O’Day S., Infante J.R., Falchook G.S., Arkenau H.T., et al.  Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436) Clin. Cancer Res. 2013;19:4868–4878. doi: 10.1158/1078-0432.CCR-13-0827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0827</ArticleId>
            <ArticleId IdType="pmc">PMC3924894</ArticleId>
            <ArticleId IdType="pubmed">23833299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trunzer K., Pavlick A.C., Schuchter L., Gonzalez R., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., Kim K.B., Weber J.S., et al.  Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 2013;31:1767–1774. doi: 10.1200/JCO.2012.44.7888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2012.44.7888</ArticleId>
            <ArticleId IdType="pubmed">23569304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allouche J., Bellon N., Saidani M., Stanchina-Chatrousse L., Masson Y., Patwardhan A., Gilles-Marsens F., Delevoye C., Domingues S., Nissan X., et al.  In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells. Proc. Natl. Acad. Sci. USA. 2015;112:9034–9039. doi: 10.1073/pnas.1501032112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1501032112</ArticleId>
            <ArticleId IdType="pmc">PMC4517235</ArticleId>
            <ArticleId IdType="pubmed">26150484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peltonen S., Kallionpaa R.A., Peltonen J. Neurofibromatosis type 1 (NF1) gene: Beyond cafe au lait spots and dermal neurofibromas. Exp. Dermatol. 2017;26:645–648. doi: 10.1111/exd.13212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/exd.13212</ArticleId>
            <ArticleId IdType="pubmed">27622733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krauthammer M., Kong Y., Bacchiocchi A., Evans P., Pornputtapong N., Wu C., McCusker J.P., Ma S., Cheng E., Straub R., et al.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat. Genet. 2015;47:996–1002. doi: 10.1038/ng.3361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3361</ArticleId>
            <ArticleId IdType="pmc">PMC4916843</ArticleId>
            <ArticleId IdType="pubmed">26214590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arafeh R., Qutob N., Emmanuel R., Keren-Paz A., Madore J., Elkahloun A., Wilmott J.S., Gartner J.J., Di Pizio A., Winograd-Katz S., et al.  Recurrent inactivating RASA2 mutations in melanoma. Nat. Genet. 2015;47:1408–1410. doi: 10.1038/ng.3427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3427</ArticleId>
            <ArticleId IdType="pmc">PMC4954601</ArticleId>
            <ArticleId IdType="pubmed">26502337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiuru M., Busam K.J. The NF1 gene in tumor syndromes and melanoma. Lab. Invest. 2017;97:146–157. doi: 10.1038/labinvest.2016.142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.2016.142</ArticleId>
            <ArticleId IdType="pmc">PMC5413358</ArticleId>
            <ArticleId IdType="pubmed">28067895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halaban R., Krauthammer M. RASopathy Gene Mutations in Melanoma. J. Investig. Dermatol. 2016;136:1755–1759. doi: 10.1016/j.jid.2016.05.095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jid.2016.05.095</ArticleId>
            <ArticleId IdType="pmc">PMC4992636</ArticleId>
            <ArticleId IdType="pubmed">27236105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whittaker S.R., Theurillat J.P., Van Allen E., Wagle N., Hsiao J., Cowley G.S., Schadendorf D., Root D.E., Garraway L.A. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013;3:350–362. doi: 10.1158/2159-8290.CD-12-0470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-12-0470</ArticleId>
            <ArticleId IdType="pmc">PMC3606893</ArticleId>
            <ArticleId IdType="pubmed">23288408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maertens O., Johnson B., Hollstein P., Frederick D.T., Cooper Z.A., Messiaen L., Bronson R.T., McMahon M., Granter S., Flaherty K., et al.  Elucidating Distinct Roles for NF1 in Melanomagenesis. Cancer Discov. 2013;3:338–349. doi: 10.1158/2159-8290.CD-12-0313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-12-0313</ArticleId>
            <ArticleId IdType="pmc">PMC3595355</ArticleId>
            <ArticleId IdType="pubmed">23171796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Staibano S., Pepe S., Soyer P., Argenziano G., Somma P., Mansueto G., Mascolo M., Bianco A.R., Laus G., De Rosa G. Epidermal growth factor receptor (EGFR) expression in cutaneous melanoma: A possible role as prognostic marker. Melanoma Res. 2004;14:S26. doi: 10.1097/00008390-200404000-00030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00008390-200404000-00030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J., Huang S.K., Marzese D.M., Hsu S.C., Kawas N.P., Chong K.K., Long G.V., Menzies A.M., Scolyer R.A., Izraely S., et al.  Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J. Investig. Derm. 2015;135:532–541. doi: 10.1038/jid.2014.418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jid.2014.418</ArticleId>
            <ArticleId IdType="pmc">PMC4307785</ArticleId>
            <ArticleId IdType="pubmed">25243790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwong L.N., Boland G.M., Frederick D.T., Helms T.L., Akid A.T., Miller J.P., Jiang S., Cooper Z.A., Song X., Seth S., et al.  Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J. Clin. Investig. 2015;125:1459–1470. doi: 10.1172/JCI78954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI78954</ArticleId>
            <ArticleId IdType="pmc">PMC4396463</ArticleId>
            <ArticleId IdType="pubmed">25705882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seshacharyulu P., Ponnusamy M.P., Haridas D., Jain M., Ganti A.K., Batra S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Targets. 2012;16:15–31. doi: 10.1517/14728222.2011.648617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14728222.2011.648617</ArticleId>
            <ArticleId IdType="pmc">PMC3291787</ArticleId>
            <ArticleId IdType="pubmed">22239438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun C., Wang L., Huang S., Heynen G.J., Prahallad A., Robert C., Haanen J., Blank C., Wesseling J., Willems S.M., et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508:118–122. doi: 10.1038/nature13121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13121</ArticleId>
            <ArticleId IdType="pubmed">24670642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross A., Niemetz-Rahn A., Nonnenmacher A., Tucholski J., Keilholz U., Fusi A. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway. Target Oncol. 2015;10:77–84. doi: 10.1007/s11523-014-0318-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11523-014-0318-9</ArticleId>
            <ArticleId IdType="pubmed">24824730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumoto K., Umitsu M., De Silva D.M., Roy A., Bottaro D.P. Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci. 2017;108:296–307. doi: 10.1111/cas.13156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.13156</ArticleId>
            <ArticleId IdType="pmc">PMC5378267</ArticleId>
            <ArticleId IdType="pubmed">28064454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porta C., Paglino C., Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014;4:64. doi: 10.3389/fonc.2014.00064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2014.00064</ArticleId>
            <ArticleId IdType="pmc">PMC3995050</ArticleId>
            <ArticleId IdType="pubmed">24782981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendoza M.C., Er E.E., Blenis J. The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem. Sci. 2011;36:320–328. doi: 10.1016/j.tibs.2011.03.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2011.03.006</ArticleId>
            <ArticleId IdType="pmc">PMC3112285</ArticleId>
            <ArticleId IdType="pubmed">21531565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blum D., LaBarge S., Reproducibility Project: Cancer Biology  Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Elife. 2014;3:e04034. doi: 10.7554/eLife.04034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.04034</ArticleId>
            <ArticleId IdType="pmc">PMC4270138</ArticleId>
            <ArticleId IdType="pubmed">25490933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500–504. doi: 10.1038/nature11183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11183</ArticleId>
            <ArticleId IdType="pmc">PMC3711467</ArticleId>
            <ArticleId IdType="pubmed">22763439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi H., Hong A., Kong X., Koya R.C., Song C., Moriceau G., Hugo W., Yu C.C., Ng C., Chodon T., et al.  A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014;4:69–79. doi: 10.1158/2159-8290.CD-13-0279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-13-0279</ArticleId>
            <ArticleId IdType="pmc">PMC3893054</ArticleId>
            <ArticleId IdType="pubmed">24265152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madhunapantula S.V., Mosca P.J., Robertson G.P. The Akt signaling pathway: An emerging therapeutic target in malignant melanoma. Cancer Biol. 2011;12:1032–1049. doi: 10.4161/cbt.12.12.18442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cbt.12.12.18442</ArticleId>
            <ArticleId IdType="pmc">PMC3335938</ArticleId>
            <ArticleId IdType="pubmed">22157148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das Thakur M., Stuart D.D. Molecular pathways: Response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors. Clin. Cancer Res. 2014;20:1074–1080. doi: 10.1158/1078-0432.CCR-13-0103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0103</ArticleId>
            <ArticleId IdType="pubmed">24352648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smalley K.S., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi S., Hansson J., Wu H., King A.J., Van Belle P., et al.  Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther. 2008;7:2876–2883. doi: 10.1158/1535-7163.MCT-08-0431.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-08-0431</ArticleId>
            <ArticleId IdType="pmc">PMC2651569</ArticleId>
            <ArticleId IdType="pubmed">18790768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manzano J.L., Layos L., Buges C., de Los Llanos Gil M., Vila L., Martinez-Balibrea E., Martinez-Cardus A. Resistant mechanisms to BRAF inhibitors in melanoma. Ann. Transl. Med. 2016;4:237. doi: 10.21037/atm.2016.06.07.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/atm.2016.06.07</ArticleId>
            <ArticleId IdType="pmc">PMC4930524</ArticleId>
            <ArticleId IdType="pubmed">27429963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson M.A., Zhao F., Khare S., Roszik J., Woodman S.E., D’Andrea K., Wubbenhorst B., Rimm D.L., Kirkwood J.M., Kluger H.M., et al.  Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2016;22:374–382. doi: 10.1158/1078-0432.CCR-15-1162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1162</ArticleId>
            <ArticleId IdType="pmc">PMC4821426</ArticleId>
            <ArticleId IdType="pubmed">26307133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris A.L., Lee S.E., Dawson L.K., Marlow L.A., Edenfield B.H., Durham W.F., Flotte T.J., Thompson M., Small D.L., Synnott A.J., et al.  Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF (V600E)-mutant melanoma. Oncotarget. 2018;9:10905–10919. doi: 10.18632/oncotarget.23649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.23649</ArticleId>
            <ArticleId IdType="pmc">PMC5834273</ArticleId>
            <ArticleId IdType="pubmed">29541385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goding C.R., Arnheiter H. MITF-the first 25 years. Genes Dev. 2019;33:983–1007. doi: 10.1101/gad.324657.119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.324657.119</ArticleId>
            <ArticleId IdType="pmc">PMC6672050</ArticleId>
            <ArticleId IdType="pubmed">31123060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leclerc J., Ballotti R., Bertolotto C. Pathways from senescence to melanoma: Focus on MITF sumoylation. Oncogene. 2017;36:6659–6667. doi: 10.1038/onc.2017.292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2017.292</ArticleId>
            <ArticleId IdType="pubmed">28825724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amaral T., Sinnberg T., Meier F., Krepler C., Levesque M., Niessner H., Garbe C. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. Eur. J. Cancer. 2017;73:93–101. doi: 10.1016/j.ejca.2016.12.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2016.12.012</ArticleId>
            <ArticleId IdType="pubmed">28162869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy C., Khaled M., Fisher D.E. MITF: Master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 2006;12:406–414. doi: 10.1016/j.molmed.2006.07.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2006.07.008</ArticleId>
            <ArticleId IdType="pubmed">16899407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen C.M., Johnson L.A., Piccioni F., Townes A., Frederick D.T., Donahue M.K., Narayan R., Flaherty K.T., Wargo J.A., Root D.E., et al.  A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013;504:138–142. doi: 10.1038/nature12688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12688</ArticleId>
            <ArticleId IdType="pmc">PMC4098832</ArticleId>
            <ArticleId IdType="pubmed">24185007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith M.P., Brunton H., Rowling E.J., Ferguson J., Arozarena I., Miskolczi Z., Lee J.L., Girotti M.R., Marais R., Levesque M.P., et al.  Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell. 2016;29:270–284. doi: 10.1016/j.ccell.2016.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2016.02.003</ArticleId>
            <ArticleId IdType="pmc">PMC4796027</ArticleId>
            <ArticleId IdType="pubmed">26977879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller J., Krijgsman O., Tsoi J., Robert L., Hugo W., Song C., Kong X., Possik P.A., Cornelissen-Steijger P.D.M., Foppen M.H.G., et al.  Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat. Commun. 2014;5:5712. doi: 10.1038/ncomms6712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms6712</ArticleId>
            <ArticleId IdType="pmc">PMC4428333</ArticleId>
            <ArticleId IdType="pubmed">25502142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konieczkowski D.J., Johannessen C.M., Abudayyeh O., Kim J.W., Cooper Z.A., Piris A., Frederick D.T., Barzily-Rokni M., Straussman R., Haq R., et al.  A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. Cancer Discov. 2014;4:816–827. doi: 10.1158/2159-8290.CD-13-0424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-13-0424</ArticleId>
            <ArticleId IdType="pmc">PMC4154497</ArticleId>
            <ArticleId IdType="pubmed">24771846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khaliq M., Fallahi-Sichani M. Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency. Cancers. 2019;11:1480.  doi: 10.3390/cancers11101480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11101480</ArticleId>
            <ArticleId IdType="pmc">PMC6826668</ArticleId>
            <ArticleId IdType="pubmed">31581557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin S.G., Xiong W., Wu X., Yang L., Pfeifer G.P. The DNA methylation landscape of human melanoma. Genomics. 2015;106:322–330. doi: 10.1016/j.ygeno.2015.09.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygeno.2015.09.004</ArticleId>
            <ArticleId IdType="pmc">PMC4666751</ArticleId>
            <ArticleId IdType="pubmed">26384656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto Y., Matsusaka K., Fukuyo M., Rahmutulla B., Matsue H., Kaneda A. Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis. Cancer Med. 2020 doi: 10.1002/cam4.3127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.3127</ArticleId>
            <ArticleId IdType="pmc">PMC7541157</ArticleId>
            <ArticleId IdType="pubmed">32406600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Micevic G., Muthusamy V., Damsky W., Theodosakis N., Liu X., Meeth K., Wingrove E., Santhanakrishnan M., Bosenberg M. DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Rep. 2016;14:2180–2192. doi: 10.1016/j.celrep.2016.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2016.02.010</ArticleId>
            <ArticleId IdType="pmc">PMC4785087</ArticleId>
            <ArticleId IdType="pubmed">26923591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al Emran A., Marzese D.M., Menon D.R., Stark M.S., Torrano J., Hammerlindl H., Zhang G., Brafford P., Salomon M.P., Nelson N., et al.  Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget. 2018;9:8206–8222. doi: 10.18632/oncotarget.23654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.23654</ArticleId>
            <ArticleId IdType="pmc">PMC5823586</ArticleId>
            <ArticleId IdType="pubmed">29492189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan J.C., Maze I. Nothing Is yet Set in (Hi)stone: Novel Post-Translational Modifications Regulating Chromatin Function. Trends Biochem. Sci. 2020 doi: 10.1016/j.tibs.2020.05.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tibs.2020.05.009</ArticleId>
            <ArticleId IdType="pmc">PMC7502514</ArticleId>
            <ArticleId IdType="pubmed">32498971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., Basu D., Gimotty P., Vogt T., Herlyn M. A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth. Cell. 2010;141:583–594. doi: 10.1016/j.cell.2010.04.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.04.020</ArticleId>
            <ArticleId IdType="pmc">PMC2882693</ArticleId>
            <ArticleId IdType="pubmed">20478252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravindran Menon D., Das S., Krepler C., Vultur A., Rinner B., Schauer S., Kashofer K., Wagner K., Zhang G., Bonyadi Rad E., et al.  A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. 2015;34:4448–4459. doi: 10.1038/onc.2014.372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2014.372</ArticleId>
            <ArticleId IdType="pmc">PMC4442085</ArticleId>
            <ArticleId IdType="pubmed">25417704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roesch A., Vultur A., Bogeski I., Wang H., Zimmermann K.M., Speicher D., Körbel C., Laschke M.W., Gimotty P.A., Philipp S.E., et al.  Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells. Cancer Cell. 2013;23:811–825. doi: 10.1016/j.ccr.2013.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2013.05.003</ArticleId>
            <ArticleId IdType="pmc">PMC3810180</ArticleId>
            <ArticleId IdType="pubmed">23764003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strub T., Ghiraldini F.G., Carcamo S., Li M., Wroblewska A., Singh R., Goldberg M.S., Hasson D., Wang Z., Gallagher S.J., et al.  SIRT6 haploinsufficiency induces BRAF(V600E) melanoma cell resistance to MAPK inhibitors via IGF signalling. Nat. Commun. 2018;9:3440. doi: 10.1038/s41467-018-05966-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-05966-z</ArticleId>
            <ArticleId IdType="pmc">PMC6109055</ArticleId>
            <ArticleId IdType="pubmed">30143629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakadia S., Yarlagadda N., Awad R., Kundranda M., Niu J., Naraev B., Mina L., Dragovich T., Gimbel M., Mahmoud F. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco Targets Ther. 2018;11:7095–7107. doi: 10.2147/OTT.S182721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S182721</ArticleId>
            <ArticleId IdType="pmc">PMC6200076</ArticleId>
            <ArticleId IdType="pubmed">30410366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tolcher A.W., Peng W., Calvo E. Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. Mol. Cancer. 2018;17:3–16. doi: 10.1158/1535-7163.MCT-17-0349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-17-0349</ArticleId>
            <ArticleId IdType="pubmed">29295962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frederick D.T., Piris A., Cogdill A.P., Cooper Z.A., Lezcano C., Ferrone C.R., Mitra D., Boni A., Newton L.P., Liu C., et al.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 2013;19:1225–1231. doi: 10.1158/1078-0432.CCR-12-1630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1630</ArticleId>
            <ArticleId IdType="pmc">PMC3752683</ArticleId>
            <ArticleId IdType="pubmed">23307859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelster M.S., Amaria R.N. Combined targeted therapy and immunotherapy in melanoma: A review of the impact on the tumor microenvironment and outcomes of early clinical trials. Adv. Med. Oncol. 2019;11:1758835919830826. doi: 10.1177/1758835919830826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1758835919830826</ArticleId>
            <ArticleId IdType="pmc">PMC6384439</ArticleId>
            <ArticleId IdType="pubmed">30815041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilmott J.S., Long G.V., Howle J.R., Haydu L.E., Sharma R.N., Thompson J.F., Kefford R.F., Hersey P., Scolyer R.A. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 2012;18:1386–1394. doi: 10.1158/1078-0432.CCR-11-2479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-2479</ArticleId>
            <ArticleId IdType="pubmed">22156613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ascierto P.A., Dummer R. Immunological effects of BRAF+MEK inhibition. Oncoimmunology. 2018;7:e1468955. doi: 10.1080/2162402X.2018.1468955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1468955</ArticleId>
            <ArticleId IdType="pmc">PMC6140547</ArticleId>
            <ArticleId IdType="pubmed">30228935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ascierto P.A., Ferrucci P.F., Stephens R., Del Vecchio M., Atkinson V., Schmidt H., Schachter J., Queirolo P., Long G.V., Di Giacomo A.M., et al.  KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. Ann. Oncol. 2018;29:viii442–viii466. doi: 10.1093/annonc/mdy289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan R.J., Hamid O., Gonzalez R., Infante J.R., Patel M.R., Hodi F.S., Lewis K.D., Tawbi H.A., Hernandez G., Wongchenko M.J., et al.  Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 2019;25:929–935. doi: 10.1038/s41591-019-0474-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0474-7</ArticleId>
            <ArticleId IdType="pubmed">31171876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long G.V., Lebbe C., Atkinson V., Mandalà M., Nathan P.D., Fernandez A.M.A., Richtig E., Yamazaki N., Robert C., Schadendorf D., et al.  The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i. J. Clin. Oncol. 2019;37(Suppl. 15):9531. doi: 10.1200/JCO.2019.37.15_suppl.9531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.9531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber J.S., Del Vecchio M., Mandala M., Gogas H., Arance A.M., Dalle S., Cowey C.L., Schenker M., Grob J.J., Chiarion-Sileni V., et al.  Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. Ann. Oncol. 2019;30:v533–v534. doi: 10.1093/annonc/mdz255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A., Butler M., Lutzky J., Lawrence D.P., Robert C., Miller W., Linette G.P., Ascierto P.A., Kuzel T., Algazi A.P., et al.  Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J. Clin. Oncol. 2015;33(Suppl. 15):3003. doi: 10.1200/jco.2015.33.15_suppl.3003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2015.33.15_suppl.3003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng P., Levesque M.P., Dummer R., Mangana J. Targeting complex, adaptive responses in melanoma therapy. Cancer Treat. Rev. 2020;86:101997. doi: 10.1016/j.ctrv.2020.101997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2020.101997</ArticleId>
            <ArticleId IdType="pubmed">32179238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McArthur G.A., Stroyakovskiy D., Gogas H., Robert C., Lewis K., Protsenko S., Pereira R., Eigentler T., Rutkowski P., Demidov L., et al.  Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial; Proceedings of the American Association for Cancer Research Virtual Annual Meeting I, Virtual Meeting I; 27–28 April 2020. Sessions Available Online.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang J., Yao Z., Jonsson P., Allen A.N., Qin A.C.R., Uddin S., Dunkel I.J., Petriccione M., Manova K., Haque S., et al.  A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF(V600E)-Mutant Brain Tumor. Cancer Discov. 2018;8:1130–1141. doi: 10.1158/2159-8290.CD-17-1263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-17-1263</ArticleId>
            <ArticleId IdType="pmc">PMC6125191</ArticleId>
            <ArticleId IdType="pubmed">29880583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luebker S.A., Koepsell S.A. Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies. Front. Oncol. 2019;9:268. doi: 10.3389/fonc.2019.00268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.00268</ArticleId>
            <ArticleId IdType="pmc">PMC6478763</ArticleId>
            <ArticleId IdType="pubmed">31058079</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
